Minimal Stimulation or Clomiphene Citrate in Treatment of Polycystic Ovary Syndrome

Minimal Stimulation or Clomiphene Citrate as First Line Therapy in Women With Polycystic Ovary Syndrome

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01157312

Enrollment

113

Registered

2010-07-07

Start date

2008-08-31

Completion date

2010-04-30

Last updated

2010-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic Ovary Syndrome

Keywords

Polycystic ovary syndrome, clomiphene citrate, minimal stimulation, infertility treatment

Brief summary

The purpose of this study is to compare and determine the the efficacy of minimal stimulation and clomiphene citrate(CC) as the first-line treatment in infertile women with Polycystic Ovary Syndrome(PCOS).

Detailed description

All patients received 100 mg CC (Clomid®; Global Napi Pharmaceuticals, Cairo, Egypt) for 5 days starting from day 3 of spontaneous or induced menstruation. In group A (minimal stimulation), 2 vials of highly purified uFSH , 150 IU (Fostimon; IBSA, Lugano, Switzerland, 75 IU/vial) were given IM on cycle day 9. A total of 3 cycles was offered to each group.

Interventions

DRUGclomiphene citrate +highly purified uFSH

DRUGclomiphene citrate

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

FEMALE

Age

20 Years to 39 Years

Healthy volunteers

Inclusion criteria

* PCOS * No other infertility factors * No previous use of ovarian stimulation drugs

Exclusion criteria

* Congenital adrenal hyperplasia * Cushing syndrome * Androgen secreting tumors

Design outcomes

Primary

Measure	Time frame
clinical pregnancy rate per cycle	—

Secondary

Measure	Time frame
endometrial thickness at the time of hCG administration	—

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026